Thank you for visiting the mAb Colorado Website!
On this website you will find the archive of products and research findings from the mAb Colorado project. However, as of May 2022 only the "Research" tab will be updated. Please contact your healthcare provider if you are trying to find monoclonal antibody treatment for COVID-19.
Published mAb Colorado RWE and D&I Findings
mAb RWE Published Manuscripts
-
Association Between Monoclonal Antibody Therapy, Vaccination, and Longer-Term Symptom Resolution After Acute COVID-19Opens in a new window
Mar 1, 2024Conclusion: COVID-19 vaccination, but not mAb therapy, was associated with a shorter time to symptom resolution. Both were associated with lower 28-day hospitalization.Opens in a new window Full story -
Effectiveness of Subcutaneous Monoclonal Antibody Treatment in Emergency Department Outpatients with COVID-19Opens in a new window
Feb 21, 2024Conclusions: Among ED patients who presented for symptomatic COVID-19 during the Delta variant phase, ED subcutaneous casirivimab/imdevimab treatment was not associated with a decrease in hospitalizations. However, treatment was associated with lower mortality at 28 and 90 days, hospital LOS, and overall severity of illness.Opens in a new window Full story -
Real-World Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During BQ.1, BQ.1.1., and XBB.1.5 Predominant Omicron Variants in Three U.S. Health Systems: A Retrospective Cohort StudyOpens in a new window
Feb 1, 2024Interpretation: Real-world evidence from major US healthcare systems suggests ongoing NMV-r effectiveness in preventing hospitalisation during a BQ.1/BQ.1.1/XBB.1.5-predominant phase in the U.S, supporting its continued use in similar patient populations.Opens in a new window Full story -
Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants, Including BA.4/BA.5Opens in a new window
Apr 16, 2023Conclusion: During the Omicron BA.2/BA.2.12.1/BA.4/BA.5 variant phase, bebtelovimab was associated with lower hospitalization.Opens in a new window Full story -
Real-world use of Nirmatrelvir-Ritonavir in Outpatients with COVID-19 During the Era of Omicron Variants Including BA.4 and BA.5 in Colorado, USA: a Retrospective Cohort StudyOpens in a new window
Feb 10, 2023Interpretation: Real-world evidence reported during a BA.2, BA2.12.1, BA.4, and BA.5 omicron surge showed an association between nirmatrelvir-ritonavir treatment and reduced 28-day all-cause hospitalisation, all-cause mortality, and visits to the emergency department. With results that are among the first to suggest effectiveness of nirmatrelvir-ritonavir for non-hospitalised patients during an omicron period inclusive of BA.4 and BA.5 subvariants, these data support nirmatrelvir-ritonavir as an ongoing first-line treatment for adults acutely infected with SARS-CoV-2.Opens in a new window Full story -
Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron PhaseOpens in a new window
Jan 25, 2023Summary: Real-world evidence demonstrates that the neutralizing monoclonal antibody sotrovimab was not associated with lower 28-day hospitalization and mortality rates when administered to high-risk outpatients recently infected with SARS-CoV-2 during the Omicron variant phase, compared to a propensity-matched cohort of untreated outpatients.Opens in a new window Full story -
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatientsOpens in a new window
Nov 7, 2022Conclusions: Comorbidities, lack of prior SARS-CoV-2 vaccination, non-Hispanic black race/ethnicity, obesity, age ≥ 65 years, and male sex are associated with treatment failure of mAbs.Opens in a new window Full story -
Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 OutpatientsOpens in a new window
Dec 13, 2022Conclusion: Real-world evidence demonstrated sotrovimab effectiveness in reducing hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta variant phase.Opens in a new window Full story -
Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 OutpatientsOpens in a new window
Oct 28, 2022Objective: To evaluate the effectiveness of mAb treatment in preventing progression to severe disease during the Delta phase of the pandemic and based on key baseline risk factors.Opens in a new window Full story
mAb D&I Published Manuscripts
-
Real-world data to evaluate effects of a multi-level dissemination strategy on access, outcomes, and equity of monoclonal antibodies for COVID-19Opens in a new window
Nov 13, 2023Conclusion: Real-world data can be used to estimate population impact of multi-level dissemination strategies.Opens in a new window Full story -
A multimodal strategy to improve race/ethnic group equity in administration of neutralizing monoclonal antibody treatment for COVID-19 outpatientsOpens in a new window
Feb 10, 2023Discussion: Implementation of multiple systematic strategies to administer COVID-19 monoclonal antibodies resulted in an equitable race/ethnic distribution of treatment.Opens in a new window Full story -
"All of the things to everyone everywhere": A mixed methods analysis of community perspectives on equitable access to monoclonal antibody treatment for COVID-19Opens in a new window
Nov 23, 2022Objective: This study assessed mAbs community awareness and opportunities for improving equitable mAb access.Opens in a new window Full story -
Referrals, access, and equity of monoclonal antibodies for outpatient COVID-19: A qualitative study of clinician perspectivesOpens in a new window
Dec 16, 2022Objective: To understand, from the clinician perspective, the factors facilitating or hindering monoclonal antibody referrals, patient access, and equity to inform development of clinician-focused messages, materials, and processes for improving access to therapeutics for COVID-19 in Colorado.Opens in a new window Full story -
Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable AccessOpens in a new window
Oct 1, 2022Objective: To assess clinician knowledge, beliefs, and experiences regarding obtaining mAb treatment for eligible patients.Opens in a new window Full story
This project was funded by a grant from the National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) (award number UL1-TR002535-03S3).